3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Sarcoma
1
Genitourinary
1
Conditions
Prostatic Neoplasms
30
Prostatic Neoplasms, Castration-Resistant
5
Neoplasm Metastasis
5
Breast Neoplasms
3
Prostate Carcinoma Metastatic to the Bone
2
Neoplasms
2
Hormone Refractory Prostate Cancer
2
Bone Metastatic Castration-resistant Prostate Cancer
2
Thyroid Neoplasms
1
Prostate Cancer Metastatic to Bone
1
Pain
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Lung Neoplasms
1
Fractures, Bone
1
Fatigue
1
Castration-resistant Prostate Cancer
1
Castrate-Resistant Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Bony Metastases From Castrate Refractory Prostate Cancer
1
Bone Neoplasms
1
Bone Metastases
1
Bone Diseases
1
Interventions
Ibandronic Acid
5
Zoledronic Acid
3
Denosumab
3
pembrolizumab
2
Sunitinib
2
Radiotherapy, Intensity-Modulated
2
Nivolumab
2
Methods
2
Interviews as Topic
2
Injections
2
Curettage
2
selinexor
1
saracatinib
1
ridaforolimus
1
radium Ra 223 dichloride
1
pegfilgrastim
1
olaparib
1
montanide ISA 51
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
endostar protein
1
cc-486
1
angiotensin I (1-7)
1
Vincristine
1
Transplantation, Homologous
1
Transplantation, Autologous
1
Transcranial Direct Current Stimulation
1
Trabectedin
1
Tomography, Spiral Computed
1
TES
1
Surveys and Questionnaires
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Bone Neoplasms
×
radium Ra 223 dichloride
×
Clear all
NCT04681144
2023-10-26
QOLRAD
Bayer
Completed
103 enrolled